Veru and its shareholders had high hopes for sabizabulin, an orally administered COVID treatment. These hopes were diminished greatly on Wednesday, when a Food and Drug Administration (FDA) advisory ...
Investors are always looking for stocks that are poised to beat at earnings season and Veru Inc. VERU may be one such company. The firm has earnings coming up pretty soon, and events are shaping up ...
Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development ...
-- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an ...
MIAMI, FL, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...
MIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...
Veru Inc. is eyeing emergency use authorization for its COVID-19 drug Sabizabulin, which is currently under FDA review. Veru Inc. shares fell around 20% to a 52-week low after reporting Q1 FY23 ...
Image source: The Motley Fool. Veru (NASDAQ:VERU) presented new regulatory feedback confirming potential U.S. approval paths for Novosarm-GLP-1 combination therapy based on either incremental weight ...
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results